本报讯(记者陈潇)近日，半岛大超炮、半岛逆时针这两款刚斩获NMPAⅢ类医疗器械注册证的重磅产品 同台亮相头部能量源医美器械企业深圳半岛医疗集团股份有限公司(以下简称"半岛医疗")2026新品发布 会北京站。 据悉，半岛大超炮与半岛逆时针，分别锁定深层支撑与浅层修护，通过医工结合的高精尖技术，实现了 从筋膜层到表皮层的全方位贯通。据悉，半岛医疗旗下产品如今远销全球70多个国家和地区、覆盖国内 外上万家医院与医美机构。 半岛医疗创始人、董事长雷晓兵表示："我们的初心朴素而坚定，就是让中国上千家医院，都能买得 起、用得起曾被国际巨头垄断的尖端医疗设备。" 这份坚守的核心，源于半岛独有的"医工结合"模式。近400人的研发团队，构建起一座连接一线临床需 求与工程技术的"桥梁"——既能精准捕捉到临床一线医生和患者的痛点诉求，又能快速将需求转化为可 落地的技术方案。 中国整形美容协会会长张斌在致辞中表示："一个行业，如果不去抓创新、搞科研，是没有希望的。半 岛在超声、激光、微针领域花大量时间持续搞创新，走科研创新这条路，走对了。尽管可能很困难，但 这条路终是宽广的。" 据悉，半岛医疗在2018年调整了研发方向：必须攻克"疗 ...

中国经济网北京1月8日讯（记者 李方） 1月7日，半岛大超炮、半岛逆时针这两款刚获得NMPA III类医 疗器械注册证的产品亮相半岛医疗2026新品发布会北京站。与此同时，半岛产品已获得美国FDA、欧盟 CE等多项认证，跻身全球主流医美市场。源自中国临床医生的实战洞察、凝聚中国工程师智慧的技术 方案，正从"跟跑"转向"并跑"，开始参与塑造全球医美器械的竞争格局。 北京医院整形外科主任、教授赵红艺指出，作为风险管理等级最高的"三类有源医疗器械"，半岛逆时针 射频皮肤治疗仪获取械三认证，是其安全性与有效性的最高标准确认。其针对面部萎缩性痤疮瘢痕的多 中心临床研究数据显示，术后三个月瘢痕改善有效率达96%，受试者满意度高达97.5%。 第三方市场研究机构沙利文的数据显示，中国已成为全球增长最快的光电抗衰市场，其中超声与射频微 针两大赛道合计占比超60%，成为行业核心增长引擎。 "相信未来，中国的医美器械企业与服务机构必将走向世界，成为全球级的品牌。我们坚定看好中国医 美行业，期待中国品牌，世界共享。"雷晓兵说。 据介绍，半岛大超炮将高分辨率智能超声影像系统与治疗流程深度融合，推出SOP 3.0精准治疗体系， 构建起 ...

发布会现场，复旦大学附属华山医院终身教授、中国医师协会皮肤科医师分会首任会长兼名誉会长郑志 忠，浙江省人民医院整形外科主任吴溯帆，江苏省中医院整形外科主任黄金龙，南京展超医疗美容诊所 创始人、院长周展超，半岛医疗创始人、董事长雷晓兵等各界人士及来自全国的医美机构代表、平台伙 伴齐聚，共同聚焦中国高端医美器械的市场化实践与全球化路径。 发布会尾声，现场隆重举行了半岛逆时针、半岛大超炮 "假一赔十"正品承诺授牌仪式，与全国首批百 余个合作伙伴共同宣誓，共同守护行业品质生命线。 双技术优势加持，打造行业爆品 自"半岛大超炮"获NMPA III类注册证一个月以来，市场关注度呈"断层式"领先态势，核心产品势能持续 高位释放，上市后便冲上多社交媒体热搜榜；首批用户自发分享体验内容与效果，收获如云好评，充分 印证了新品的市场认可度与爆款潜质。 沙利文大中华区执行董事刘章川基于市场调研给出行业洞察："中国是全球增长最快的光电抗衰市场， 超声技术已成为最具潜力的细分领域，而射频微针作为综合射频产品，正稳步取代旧款设备，半岛双品 的双重优势高度契合这一趋势。" 他同时提到，99.7% 的消费者认为抗衰重要，其中抗衰先行者年均医 ...

Core Insights - The article highlights the significant advancements in China's medical aesthetics industry, particularly the achievements of a Shenzhen-based company in developing domestically produced ultrasound and radiofrequency medical devices that have received both NMPA and FDA certifications [1][2][3]. Group 1: Technological Breakthroughs - The first domestically produced ultrasound skin treatment device has received Class III certification, while the radiofrequency skin treatment device "Half Island Counterclockwise" is the first in China to obtain both NMPA and FDA approvals [1]. - The "Half Island Big Super Cannon" integrates various treatment handles and heads, enhancing treatment comfort and effectiveness, supported by clinical data showing an 82% effectiveness rate and 88% satisfaction rate from 204 cases [1]. - The radiofrequency microneedle device demonstrated a 96% effectiveness rate in scar improvement and a 98.75% patient satisfaction rate from 180 cases [1][2]. Group 2: Industry Evolution - Over the past 17 years, the company has transitioned from relying on foreign medical equipment to becoming a leader in the global medical aesthetics market, with a significant increase in R&D investment and patent applications [3]. - The company currently has a central R&D team of 180 members, with plans to increase the number of medical professionals to 65 by 2026, and has a notable share of global patent applications in the medical aesthetics sector [3]. - The company's ultrasound devices are now used in nearly 6,000 hospitals nationwide, and the radiofrequency microneedle has reached approximately 4,000 medical institutions, with user numbers projected to exceed 1 million by 2025 [3]. Group 3: Innovation Ecosystem - Shenzhen's innovation ecosystem has played a crucial role in the company's success, supported by policies, capital, and a rich clinical resource environment [4]. - The company has been recognized as a "national-level specialized and innovative small giant" and has received national-level intellectual property advantages, contributing to the growth of Shenzhen's high-end medical device industry [4]. - The company has published nearly 100 academic papers, with over 30 in SCI journals, and has participated in developing industry standards, promoting the standardization of the sector [4]. Group 4: Future Outlook - The year 2026 is anticipated to be pivotal for the medical aesthetics industry, focusing on compliance and high-quality development [7]. - The company emphasizes training for doctors and consumer education, with a rigorous certification system for device operation, ensuring standardized application of technology [7]. - The case reflects the broader trend of China's medical aesthetics industry evolving from imitation to innovation, aiming for international competitiveness [7].

近日，在半岛医疗 2026 年新品发布会上，公司两款重磅产品 —— 半岛大超炮、半岛逆时针一一亮 相。 其中，半岛大超炮是首个拿到了 国家药监局 三类医疗器械注册证的聚焦超声皮肤治疗仪，而半岛逆 时针则是首个拥有 国家药监局 NMPA 与美国 FDA 双认证的国产三类射频皮肤治疗仪。 这两款产品均凝结了公司多年的技术攻坚与研发创新成果。在业内看来，这两款产品的出现，正在引 领 医 美医疗设备行业进一步走向规范，同时也代表着国产 医美设备 技术正在逆袭，迈入全球市场 竞争。 在 颜值经济 浪潮席卷下，伴随着光电技术等发展，轻医美正在重塑 医 美市场格局。光电 医 美也因 创伤小、恢复快、适合皮肤日常管理，深受消费者追捧。 引领行业走向规范 早在 2012 年，半岛医疗便前瞻性将聚焦超声、射频技术作为未来十年的主攻技术方向 。 此次半岛医疗推出的半岛大超炮、半岛逆时针，是产品技术多次迭代后的成果，并且经过了严谨的临 床试验验证。 2021 年，半岛医疗便前瞻性启动三类临床与注册申请，系统开展临床试验，成为当时国内极少数探 索三类注册证的 医 美器械企业。 医疗器械的注册认证，三类认证与心脏起搏器、人工关节等植入式 ...

Core Insights - Peninsula Medical has launched two significant products, the Peninsula Super Cannon and the Peninsula Counterclockwise, which are set to lead the medical aesthetics equipment industry towards standardization and represent a breakthrough for domestic technology in the global market [1][4][27]. Product Launch - The Peninsula Super Cannon is the first ultrasound skin treatment device to receive a Class III medical device registration from the Chinese National Medical Products Administration (NMPA) [1][27]. - The Peninsula Counterclockwise is the first domestic Class III radiofrequency skin treatment device to achieve dual certification from both the NMPA and the U.S. FDA [1][27]. Industry Impact - The introduction of these products is seen as a move towards standardization in the medical aesthetics industry, which is increasingly influenced by the "beauty economy" and advancements in photonic technology [5][12]. - The medical aesthetics equipment market in China has significant growth potential, with the penetration of photonic medical aesthetics technology driving the development of downstream services [16][30]. Research and Development - Peninsula Medical has invested heavily in R&D, allocating over 25% of its revenue annually, and has a dedicated R&D team of nearly 400 people, constituting 30% of its total workforce [21][27]. - The company has filed over 1,000 domestic and international patents, with more than 400 granted, establishing a strong technological moat [21]. Clinical Validation - The clinical trials for the Peninsula Super Cannon involved 204 subjects, showing an efficacy rate of over 82% in improving skin laxity, with a satisfaction rate exceeding 88% three months post-treatment [7][9]. - The clinical data for the Peninsula Counterclockwise indicated a scar improvement efficacy rate of over 96% and a satisfaction rate close to 98% three months after the procedure [9]. Market Position - Peninsula Medical has positioned itself among the top six global energy source medical aesthetics equipment companies, with its products sold in over 70 countries and regions, serving more than 10,000 well-known hospitals [27]. - The launch of these products marks a shift in the domestic medical aesthetics equipment landscape, moving from low-end market competition to achieving international certifications and recognition [27][30].

Core Viewpoint - The article highlights the rapid growth of China's medical aesthetics equipment industry, showcasing the emergence of domestic brands like Peninsula Medical, which are gaining market share and technological advancements in the field [3][19]. Industry Growth - The domestic medical aesthetics equipment market is projected to exceed 32 billion yuan by 2024, with a compound annual growth rate (CAGR) of 13%-15% [3]. - The market share of domestic equipment has increased from 38% in 2020 to 42% in 2024, with energy source segments like radiofrequency and intense pulsed light reaching a 46% share [3]. Product Innovation - Peninsula Medical's two core products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, represent significant advancements in energy source medical aesthetics devices, with a focus on clinical needs and technological innovation [3][5]. - The Peninsula Ultra Cannon is the first and only ultrasound medical aesthetics device to receive NMPA Class III certification, achieving precise anti-aging treatment from the epidermis to the SMAS layer [3][5]. - The Peninsula Counterclockwise is the first domestic radiofrequency medical aesthetics device to obtain NMPA Class III certification, featuring innovative technologies for effective treatment [5][7]. Clinical Research and Efficacy - Clinical studies led by top hospitals show that the Peninsula Ultra Cannon has an effectiveness rate of over 89% in improving skin laxity, with a satisfaction rate exceeding 90% among participants [5]. - Since its launch in 2021, the Peninsula Ultra Cannon has been used in over 4 million treatments, averaging more than 3,000 treatments per day [5]. R&D and Patents - Peninsula Medical has a strong focus on R&D, with nearly 400 staff dedicated to research, accounting for 30% of total employees, and R&D investment representing 25%-27% of sales revenue [9]. - The company has filed over 1,000 domestic and international patents, with more than 70 global certifications, and has played a role in drafting industry standards [9][19]. International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of China's medical aesthetics professionals [11]. - Peninsula Medical's collaboration with Boston Aesthetics aims to bridge the gap between Chinese R&D and U.S. clinical needs, facilitating the entry of Chinese products into the global market [12][18]. Market Trends - The export value of domestic medical aesthetics equipment is expected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [19]. - The industry is transitioning from a focus on cost-effectiveness to differentiation, with domestic companies targeting specific needs of Asian skin types [14][19]. Future Outlook - The integration of artificial intelligence with medical aesthetics devices is emerging as a new trend, enabling personalized treatment parameters [19]. - The industry is poised for a comprehensive upgrade from "Made in China" to "Intelligent Manufacturing in China," driven by companies focused on R&D and clinical needs [19].

Core Insights - Peninsula Medical showcased its brand on the Nasdaq screen, highlighting its rapid growth in the Chinese medical aesthetics industry, with the domestic medical aesthetic equipment market projected to exceed 32 billion yuan by 2024, maintaining a compound annual growth rate of 13%-15% [1][11] - The company presented two NMPA Class III certified products, the Peninsula Ultra Cannon and Peninsula Counterclockwise, in collaboration with Boston Aesthetics and numerous Chinese dermatologists and plastic surgeons [1][2] Industry Growth - The domestic medical aesthetic equipment market is expected to grow significantly, with the share of domestic equipment increasing from 38% in 2020 to 42% in 2024, particularly in energy source segments like RF and IPL, where domestic brands now hold a 46% market share [1][11] - The clinical demand drives technological innovation, with Peninsula Medical focusing on addressing industry pain points through medical-engineering collaboration [2][3] Product Innovation - The Peninsula Ultra Cannon is the first globally to receive NMPA Class III certification for ultrasound medical aesthetics, achieving over 89% effectiveness in improving skin laxity in clinical studies [2][3] - The Peninsula Counterclockwise is the first domestic RF medical aesthetic device to receive NMPA Class III certification, featuring innovative technologies for precise depth control in clinical applications [3][4] Research and Development - Peninsula Medical has a robust R&D team of nearly 400, accounting for 30% of its workforce, with R&D investment constituting 25%-27% of sales revenue, which is high for the industry [4][5] - The company has filed over 1,000 domestic and international patents and has received more than 70 global certifications, contributing to the industry's shift from imitation to independent innovation [5][11] International Expansion - The presence of Chinese dermatologists and plastic surgeons on the Nasdaq screen signifies the increasing international participation of Chinese medical aesthetics professionals [6][11] - Peninsula Medical's Boston Aesthetics team is pivotal in bridging Chinese R&D with U.S. clinical needs, having successfully registered the Peninsula Counterclockwise in the U.S. [7][10] Market Trends - The international competitiveness of domestic devices is shifting from cost-effectiveness to differentiated advantages, focusing on the unique characteristics of Asian skin [8][9] - The export value of domestic medical aesthetic devices is projected to grow by 35% in 2024, with energy source devices making up 42% of exports, expanding into high-end markets like Europe and the U.S. [11]

Core Insights - The strategic partnership between Yuansong Group and Peninsula Medical marks the launch of China's first approved Class III ultrasonic medical beauty device, enhancing compliance in the aesthetic medicine market [1][2] - The Chinese aesthetic medicine industry has reached a market size of hundreds of billions, with the non-invasive anti-aging sector experiencing double-digit growth, despite challenges such as equipment qualification and quantifiable results [1] Group 1: Strategic Partnership - The collaboration aims to integrate Peninsula Medical's 14 years of research in developing the first Class III ultrasonic medical beauty device with Yuansong's established compliance service system [1] - The "Half Island Super Cannon" received approval for Class III medical device registration at the end of October, becoming the first ultrasonic medical beauty device in China to obtain this certification [1] Group 2: Compliance and Service - Yuansong's competitive advantage lies in the dual assurance of compliant equipment and transparent services, filling a gap in the compliant ultrasonic anti-aging service sector [2] - The company has established nearly 30 direct-operated clinics in 20 major cities, serving over one million consumers, and has formed strategic partnerships with several listed companies to promote high-standard products [2]

Core Viewpoint - The Chinese medical aesthetics device industry is entering a new development stage characterized by high standards, strong regulation, and genuine innovation, as evidenced by the approval of the first "Class III Medical Device" registration certificate for ultrasound aesthetic equipment by the National Medical Products Administration (NMPA) [1][2]. Industry Overview - The approval of the first "Class III Medical Device" certificate marks a significant shift in the medical aesthetics device market, moving towards a high-standard and highly regulated environment [2][4]. - The certification process for Class III medical devices is rigorous, comparable to that of implantable products like pacemakers and artificial joints, requiring comprehensive evidence across the entire product lifecycle [2][3]. Company Insights - The company, Peninsula Medical, has spent over a decade focusing on clinical needs and technology development, positioning itself as a leader in innovation and compliance within the domestic energy source medical aesthetics device sector [1][3]. - Peninsula Medical's commitment to compliance and high standards has allowed it to be one of the few companies to successfully navigate the Class III certification process, having initiated its clinical and registration applications as early as 2021 [3][8]. Market Dynamics - The introduction of the "Class III Medical Device" certificate is expected to reshape market competition and accelerate industry consolidation, with companies that obtain this certification gaining significant advantages in the market [5][12]. - The high technical barriers and market exclusivity associated with the "Class III Medical Device" certification are anticipated to drive revenue growth for certified companies, as downstream medical aesthetic institutions will prioritize products with this certification [5][12]. Technological Advancements - Peninsula Medical has made several original technological breakthroughs, including the "shadow launch technology" and "intelligent ultrasound imaging system," which enhance treatment precision and comfort [7][8]. - The company invests over 25% of its revenue into research and development, employing a large team of nearly 400 R&D personnel, which is among the highest ratios in the industry [7][8]. Global Expansion - Peninsula Medical is expanding its reach into global markets, having received FDA approval for its products and entering prestigious institutions in the United States, reflecting its transition from a domestic equipment manufacturer to a global trusted brand [11][12].